These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 30350533)

  • 1. Cytomegalovirus pleuropericarditis after orthotopic liver transplantation.
    Meesters J; Beckers L; Francque S; Roeyen G; De Greef K; Hartman V; Michielsen P; Dams K; Vanwolleghem T
    Acta Gastroenterol Belg; 2018; 81(3):427-429. PubMed ID: 30350533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ganciclovir and Foscarnet Therapy of Cytomegalovirus-Associated Meningoencephalitis in a Hemodialysis Patient With Liver Transplantation: Case Report.
    Kang GW; Hong HL; Lee IH; Ahn KS; Kim JD; Choi DL
    Transplant Proc; 2016 May; 48(4):1208-11. PubMed ID: 27320588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful treatment with foscarnet for ganciclovir-resistant cytomegalovirus infection in a kidney transplant recipient: A case report.
    Iwami D; Ogawa Y; Fujita H; Morita K; Sasaki H; Oishi Y; Higuchi H; Hatanaka K; Shinohara N
    Nephrology (Carlton); 2016 Jul; 21 Suppl 1():63-6. PubMed ID: 26970406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytomegalovirus Disease After Liver Transplant-A Description of a Treatment-Resistant Case: A Case Report and Literature Review.
    Czarnecka P; Czarnecka K; Tronina O; Durlik M
    Transplant Proc; 2018 Dec; 50(10):4015-4022. PubMed ID: 30577306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of cytomegalovirus infection after living donor liver transplantation.
    Yamanouchi K; Eguchi S; Takatsuki M; Kamohara Y; Hidaka M; Miyazaki K; Inokuma T; Tajima Y; Kanematsu T
    Hepatogastroenterology; 2012; 59(113):231-4. PubMed ID: 22251542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?
    Jain A; Orloff M; Kashyap R; Lansing K; Betts R; Mohanka R; Menegus M; Ryan C; Bozorgzadeh A
    Transplant Proc; 2005 Sep; 37(7):3182-6. PubMed ID: 16213344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Should recurrent Cytomegalovirus infections in patients with liver transplantation be treated?].
    Tarp BD; Astrup LB
    Ugeskr Laeger; 1997 May; 159(22):3413-6. PubMed ID: 9199030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delayed-onset primary cytomegalovirus disease after liver transplantation.
    Arthurs SK; Eid AJ; Pedersen RA; Dierkhising RA; Kremers WK; Patel R; Razonable RR
    Liver Transpl; 2007 Dec; 13(12):1703-9. PubMed ID: 18044717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A short-term preemptive treatment for cytomegalovirus infection in seropositive patients after liver transplantation.
    Dahiya D; Lee CF; Chan KM; Wu TJ; Chou HS; Cheng SS; Lee WC
    J Hepatobiliary Pancreat Sci; 2011 Jan; 18(1):32-8. PubMed ID: 20499109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leflunomide as a rescue treatment in ganciclovir-resistant cytomegalovirus infection in a seronegative renal transplant recipient--a case report.
    Ciszek M; Mucha K; Foroncewicz B; Chmura A; Pączek L
    Ann Transplant; 2014 Jan; 19():60-3. PubMed ID: 24481271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of cytomegalovirus infection after solid-organ or stem-cell transplantation. Current guidelines and future prospects.
    Hebart H; Kanz L; Jahn G; Einsele H
    Drugs; 1998 Jan; 55(1):59-72. PubMed ID: 9463790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytomegalovirus infection: its incidence and management in cytomegalovirus-seropositive living related liver transplant recipients: a single-center experience.
    Wadhawan M; Gupta S; Goyal N; Vasudevan KR; Makki K; Dawar R; Sardana R; Lal N; Kumar A
    Liver Transpl; 2012 Dec; 18(12):1448-55. PubMed ID: 22903934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylaxis versus pre-emptive treatment for prevention of cytomegalovirus infection in CMV-seropositive orthotopic liver-transplant recipients.
    Mengelle C; Rostaing L; Weclawiak H; Rossignol C; Kamar N; Izopet J
    J Med Virol; 2015 May; 87(5):836-44. PubMed ID: 25655981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of CMV-DNA in peripheral blood leukocytes of liver transplant patients after ganciclovir treatment.
    Loginov R; Höckerstedt K; Lautenschlager I
    Arch Virol; 2003 Jul; 148(7):1269-74. PubMed ID: 12827460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of cytomegalovirus prophylaxis on rejection following orthotopic liver transplantation.
    Slifkin M; Ruthazer R; Freeman R; Bloom J; Fitzmaurice S; Fairchild R; Angelis M; Cooper J; Barefoot L; Rohrer R; Snydman DR
    Liver Transpl; 2005 Dec; 11(12):1597-602. PubMed ID: 16315314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir.
    Razonable RR; Rivero A; Rodriguez A; Wilson J; Daniels J; Jenkins G; Larson T; Hellinger WC; Spivey JR; Paya CV
    J Infect Dis; 2001 Dec; 184(11):1461-4. PubMed ID: 11709790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small bowel transplantation complicated by cytomegalovirus tissue invasive disease without viremia.
    Avsar Y; Cicinnati VR; Kabar I; Wolters H; Anthoni C; Schmidt HH; Beckebaum S
    J Clin Virol; 2014 Jun; 60(2):177-80. PubMed ID: 24703746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients.
    Winston DJ; Busuttil RW
    Transplantation; 2003 Jan; 75(2):229-33. PubMed ID: 12548129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment with ganciclovir for cytomegalovirus duodenitis following allogenic bone marrow transplantation.
    Ahn JH; Lee JH; Lee KH; Kim WK; Lee JS; Bahng H; Jung HY; Kim YS; Kim O; Kim SH
    Korean J Intern Med; 1999 Jan; 14(1):91-4. PubMed ID: 10063321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of sirolimus-based immunosuppression vs. conventional prophylaxis therapy on cytomegalovirus infection after liver transplantation.
    Sheng L; Jun S; Jianfeng L; Lianghui G
    Clin Transplant; 2015 Jun; 29(6):555-9. PubMed ID: 25851741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.